These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11151796)

  • 1. Cardiac allograft vasculopathy--a changing perspective.
    Russell ME
    Z Kardiol; 2000; 89 Suppl 9():IX/6-10. PubMed ID: 11151796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac allograft vasculopathy--the cellular attack.
    Hutchinson IV
    Z Kardiol; 2000; 89 Suppl 9():IX/16-20. PubMed ID: 11151784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac allograft vasculopathy--problem and model.
    von Scheidt W
    Z Kardiol; 2000; 89 Suppl 9():IX/2-5. PubMed ID: 11151785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac allograft vasculopathy: a donor or recipient induced pathology?
    van den Hoogen P; Huibers MM; Sluijter JP; de Weger RA
    J Cardiovasc Transl Res; 2015 Mar; 8(2):106-16. PubMed ID: 25652948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac allograft vasculopathy in partially inbred miniature swine. I. Time course, pathology, and dependence on immune mechanisms.
    Madsen JC; Sachs DH; Fallon JT; Weissman NJ
    J Thorac Cardiovasc Surg; 1996 Jun; 111(6):1230-9. PubMed ID: 8642825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenetic mechanisms of cardiac allograft vasculopathy--impact of nitric oxide.
    Koglin J
    Z Kardiol; 2000; 89 Suppl 9():IX/24-7. PubMed ID: 11151787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
    Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunology insights into cardiac allograft rejection.
    Savasta M; Lentini S
    Rev Cardiovasc Med; 2011; 12(2):e68-76. PubMed ID: 21796085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of morbidity and mortality from cardiac allograft vasculopathy.
    Deng MC; Baba HA; Plenz G; Erren M; Wilhelm MJ; Moennig G; Scheld HH
    Z Kardiol; 2000; 89 Suppl 9():IX/63-5. PubMed ID: 11151797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
    J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of donor and recipient gender on cardiac allograft vasculopathy. An intravascular ultrasound study.
    Mehra MR; Stapleton DD; Ventura HO; Escobar A; Cassidy CA; Smart FW; Collins TJ; Ramee SR; White CJ
    Circulation; 1994 Nov; 90(5 Pt 2):II78-82. PubMed ID: 7955289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac allograft vasculopathy.
    Rhodes LR
    Crit Care Nurs Q; 2004; 27(1):10-6. PubMed ID: 14974521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of chronic cardiac allograft rejection.
    Costello JP; Mohanakumar T; Nath DS
    Tex Heart Inst J; 2013; 40(4):395-9. PubMed ID: 24082367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac allograft vasculopathy: do adipocytes bridge alloimmune and metabolic risk factors?
    Wehner JR; Baldwin WM
    Curr Opin Organ Transplant; 2010 Oct; 15(5):639-44. PubMed ID: 20689436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac allograft vasculopathy. Association with cell-mediated but not humoral alloimmunity to donor-specific vascular endothelium.
    Hosenpud JD; Everett JP; Morris TE; Mauck KA; Shipley GD; Wagner CR
    Circulation; 1995 Jul; 92(2):205-11. PubMed ID: 7600652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of chronic rejection in heart transplantation: important elements of pathogenesis and future treatments.
    Suzuki J; Isobe M; Morishita R; Nagai R
    Circ J; 2010 Feb; 74(2):233-9. PubMed ID: 20009354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riboflavin-mediated reduction of oxidant injury, rejection, and vasculopathy after cardiac allotransplantation.
    Iwanaga K; Hasegawa T; Hultquist DE; Harada H; Yoshikawa Y; Yanamadala S; Liao H; Visovatti SH; Pinsky DJ
    Transplantation; 2007 Mar; 83(6):747-53. PubMed ID: 17414708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells play a critical role in cardiac allograft vasculopathy in an interleukin-6--dependent manner.
    Zhang ZX; Huang X; Jiang J; Lian D; Min WP; Liu W; Haig A; Jevnikar AM
    Transplantation; 2014 Nov; 98(10):1029-39. PubMed ID: 25286056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression.
    Raichlin E; Bae JH; Kushwaha SS; Lennon RJ; Prasad A; Rihal CS; Lerman A
    J Am Coll Cardiol; 2009 Apr; 53(15):1279-86. PubMed ID: 19358941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4-positive helper T lymphocytes mediate mouse cardiac allograft rejection independent of donor alloantigen specific cytotoxic T lymphocytes.
    Bishop DK; Chan S; Li W; Ensley RD; Xu S; Eichwald EJ
    Transplantation; 1993 Oct; 56(4):892-7. PubMed ID: 8212213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.